You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
|
---|---|
Published in |
BMC Cancer, July 2014
|
DOI | 10.1186/1471-2407-14-521 |
Pubmed ID | |
Authors |
Gunnar Folprecht, Susanne Hamann, Katharina Schütte, Tanja Trarbach, Jan Stoehlmacher-Williams, Gerhard Ehninger |
Abstract |
The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC). Adding cetuximab to FOLFOX or FOLFIRI increased efficacy in patients with k-ras wild type mCRC. We explored the dose limiting toxicity and feasibility of the combination cetuximab, irinotecan, oxaliplatin, 5-FU and FA in mCRC patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 2 | 4% |
Brazil | 1 | 2% |
Unknown | 42 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 7 | 16% |
Student > Bachelor | 6 | 13% |
Student > Ph. D. Student | 5 | 11% |
Lecturer | 4 | 9% |
Researcher | 4 | 9% |
Other | 11 | 24% |
Unknown | 8 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 33% |
Biochemistry, Genetics and Molecular Biology | 5 | 11% |
Nursing and Health Professions | 5 | 11% |
Agricultural and Biological Sciences | 5 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Other | 4 | 9% |
Unknown | 8 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2014.
All research outputs
#18,375,064
of 22,758,963 outputs
Outputs from BMC Cancer
#5,419
of 8,277 outputs
Outputs of similar age
#163,610
of 228,925 outputs
Outputs of similar age from BMC Cancer
#95
of 143 outputs
Altmetric has tracked 22,758,963 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,277 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,925 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 143 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.